Dr. David Samadi is the best prostate surgeon that has been successful in treating prostate cancer using the Da Vinci robotic system. He is the chair of urology department and chief of robotic surgery at Lenox Hill hospital. He was born and raised in Iran but was forced to relocate to Belgium because of the 1979 revolution in Iran. He was separated from his parents but remained with his brother and sister. He later transferred to America, and he now lives in Old Westbury New York.
He finished his high school in Rosalyn New York and joined Broke University where he got his degree in biochemistry. He joined Stony Brook University where he did his masters in 1994. He went to Montefiore medical center for postgraduate training. To get his specialization, he joined Memorial Sloan Kettering cancer center for proctology training. He went to France for the robotic radical prostatectomy in Henri Mondor Creteil. He developed a smart technique called Da Vinci Surgical system that was to replace open surgery. This modified advanced robotic treatment magnifies the surgical field to give better visualization to the surgeon.
Dr. David Samadi is also known as a celebrity doctor because of the TV show he hosts on fox news channel called Sunday house call. Dr. David Samadi TV has been airing for five years every Sunday at 12:30 pm EST. The show deals with medical and health-related issues. The social media presence of the doctor is like of any other celebrity. He has Facebook and twitter account as well as a Youtube channel that he uses to communicate with the rest of the world. People have the advantage of asking him questions related to health on any social media platforms, and he answers them. He has received several awards the recent being Best urologist in New York in 2018, Castle Connolly Top Doctors in 2013 and 2014, and America’s Top Doctors for Cancer from 2009 to 2013 among many others. New York magazine named him the best doctor in 2009. Forbes magazine has also listed him among the best doctors.
Dr. David Samadi after the announcement of Mitt Romney the former Republican presidential nominee that he had undergone prostate surgery, said that finding a qualified and experienced urologist after being diagnosed with the disease is fundamental because they would help them in making decisions on what is the best medication to beat cancer. He advised that surgery is a more preferred choice over radiation because they can have almost 100% survival rate. He said that he believes there is future in robotics and medical integration in an interview with Idea Mensch. He also encouraged technologists to venture into the field.
Dr. David Samadi info: www.huffingtonpost.com/author/dr-david-samadi
The founder, President and the CEO of Seattle Genetics Clay Siegall, has been appointed as an outside director in one of the largest biotechnology company, Mirna Therapeutics that specializes in developing and commercializing MicroRNA therapeutics.
According to the Chief Executive Officer of Mirna Therapeutics Paul Lammers, everyone at the company is excited about having Siegall as part of their distinguished board of directors. Siegall has more than enough experience in the pharmaceutical industry. His success in building an oncology company will be invaluable to Mirna’s team and will guide the company to its advancement in the development of MicroRNA-based therapeutics.
Micro-RNA therapeutics is an extensive cancer research field that’s expected to position the company as a strong pipeline of product candidates. Given the company’s early involvement in miRNA field, the arrival of Siegall will propel the working of the team to advance its favorable programs for patients already in needs.
Clay Siegall established Seattle Genetics immediately after graduating from the George Washington University and the University of Maryland, where he studied Genetics and Zoology respectively in 1998. Under his leadership, the company created a diverse pipeline of antibody-based therapies that addressed immediate medical needs of cancer patients. Seattle Genetics launched its first commercial product designated ADCETRIS in 2011.
After operating for a few years, the company engaged in a few strategic partnerships with several pharmaceutical and biotechnology companies on oncology. Among these companies include Bayer and Progenics, Genentech, CuraGen, and Medlmmune. The company raised capital through private and public financings and in 2012, Clay Siegall secured over $675 million, including its initial public offering in 2012.
Apart from Seattle Genetics, Clay Siegall has founded a couple of other research institutes including National Cancer Institute, Bristol-Myers Squibb Pharmaceutical Research Institute and the National Institute of Health between 1991 and 1998.
Presently, he is a member of the board of directors at Washington Biotechnology and Biomedical Association, the Chairman of the Alder BioPharmaceuticals, and a member of the board of governors of the Fred Hutchinson Cancer Research Institute.